Combinations of cytotoxic agents including fluoropyrimidine (FP), oxaliplatin and/or irinotecan in combination with either anti-VEGF or, for RAS WT tumors, anti-EGFR antibodies represent the current standard of first-line treatment for patients with metastatic colorectal cancer (mCRC) [3]. This evidence concerns the gene EGFR and metastatic colorectal cancer.